In numbers - last quarter's share price fallers

While pharma and biotech shares have generally been buoyant in recent months, certain precipitous price drops could shine a light on the prospects for stockholders.

In October, Minerva Neurosciences (Nasdaq: NERV) fell nearly a third after a pipeline update revealed that a Phase III study of key asset MIN-101 (roluperidone) was to be put back due to a cyberattack on a contractor.

As a result, the schizophrenia drug developer was prevented from providing a first look at data in 2019, and instead expects to deliver top-line data in the first six months of 2020, resulting in a blow to financing plans predicated on a favorable year-end dataset.